Wayne, PA – March 19, 2024 — NanoCell Therapeutics, Inc. (“NanoCell”), a company developing in-vivo cell engineering solutions based on its proprietary non-viral, DNA-based gene therapy platform, today announced the appointment of Charles F. Albright, Ph.D., to its Scientific Advisory Board.
“We’re honored to welcome Charles, a globally recognized scientist with a distinguished career in biotechnology and pharmaceuticals, to NanoCell’s Scientific Advisory Board,” said Maurits Geerlings, NanoCell’s Chief Executive Officer. “Charles is contributing to the scientific diversity of our board with his deep expertise in gene editing, gene delivery and drug discovery. He will bring significant value as we are expanding our pipeline in oncology and autoimmune diseases through our innovative in-vivo cell engineering platform.”
Dr. Albright is the Chief Scientific Officer at Affinia Therapeutics, leading the creation of innovative AAV vectors for gene therapy. Previously, as Executive Vice President and Chief Scientific Officer at Editas Medicine, he played a pivotal role in pioneering CRISPR gene editing therapies, following his position as Vice President at Bristol-Myers Squibb Company, focusing on Genetically Defined Diseases and Genomics. Dr. Albright’s contributions include advancing genetic disease and cancer treatments, notably his work on the first IND for in vivo CRISPR/Cas9 editing.
“NanoCell’s in-vivo gene therapy platform is a versatile non-viral, DNA based technology targeting cancer and autoimmune diseases by enabling direct, in-body cell engineering,” said Dr. Charles. “I am pleased to join the Company at this exciting stage as a member of the Scientific Advisory Board and help advance this innovative technology to make a difference in the lives of people impacted by cancer and other serious diseases.”
About NanoCell Therapeutics, Inc.
NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. We are dedicated to pioneering transformative in-vivo cell engineering through our non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases. NanoCell’s advanced technology platform aims to evolve and enhance traditional adoptive cell therapy methods into advanced in-vivo treatments. Our objective is to streamline the overall treatment process, bolstering patient access, potential clinical benefits, and cost-effective manufacturing. For more information, visit: http://www.nanocelltx.com.
Investor Relations & Media
A. Lindman, MBA
+31 (0) 70 3643095
contact@nanocelltx.com